Literature DB >> 8751725

Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.

V Hack1, A Gross, R Kinscherf, M Bockstette, W Fiers, G Berke, W Dröge.   

Abstract

Excessive urea excretion associated with a negative nitrogen balance and massive loss of skeletal muscle mass (cachexia) is a frequent life threatening complication in malignancies and HIV infection. As these patients have often elevated interleukin-6 (IL-6) and abnormally low cystine levels, we have now determined the intracellular levels of glutathione and other cysteine derivatives in the liver and muscle tissue of IL-6-treated or tumor-bearing C57BL/6 mice. IL-6 treatment or inoculation of the MCA-105 fibrosarcoma caused a significant increase in hepatic gamma-glutamyl-cysteine synthetase activity and a decrease in the sulfate level, glutamine/urea ratio, and glutamine/glutamate ratio, suggesting that a decrease of the proton generating cysteine catabolism in the liver may increase carbamoyl-phosphate synthesis and urea formation at the expense of net glutamine synthesis. Treatment with cysteine, conversely, caused an increase in sulfate, glutamine/urea ratios, and glutamine/glutamate ratios and may thus be a useful therapeutic tool in clinical medicine. In contrast to the liver, muscle tissue of tumor-bearing mice showed decreased glutathione and increased sulfate levels, suggesting that the cysteine pool may be drained by an increased cysteine catabolism in this tissue. The findings indicate that tumor cachexia is triggered initially by IL-6 and is later sustained by processes driven by an abnormal cysteine metabolism in different organs.-Hack, V., Gross, A., Kinscherf, R., Bockstette, M., Fiers, W., Berke, G., and Dröge, W. Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8751725     DOI: 10.1096/fasebj.10.10.8751725

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  11 in total

1.  Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease.

Authors:  B Sido; V Hack; A Hochlehnert; H Lipps; C Herfarth; W Dröge
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 2.  Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology.

Authors:  Olav A Christophersen; Anna Haug
Journal:  Lipids Health Dis       Date:  2011-01-20       Impact factor: 3.876

3.  Individual variation and intraclass correlation in arachidonic acid and eicosapentaenoic acid in chicken muscle.

Authors:  Anna Haug; Ingrid Olesen; Olav A Christophersen
Journal:  Lipids Health Dis       Date:  2010-04-15       Impact factor: 3.876

4.  l-carnitine and cancer cachexia: Clinical and experimental aspects.

Authors:  Renata Silvério; Alessandro Laviano; Filippo Rossi Fanelli; Marília Seelaender
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-01-26       Impact factor: 12.910

5.  Optimal management of cancer anorexia-cachexia syndrome.

Authors:  Josep M Argilés; Mireia Olivan; Sílvia Busquets; Francisco Javier López-Soriano
Journal:  Cancer Manag Res       Date:  2010-01-22       Impact factor: 3.989

6.  Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase.

Authors:  Charles O Brown; Kelley Salem; Brett A Wagner; Soumen Bera; Neeraj Singh; Ajit Tiwari; Amit Choudhury; Garry R Buettner; Apollina Goel
Journal:  Biochem J       Date:  2012-06-15       Impact factor: 3.857

7.  Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia.

Authors:  Thomas L Schmitt; Marcus E Martignoni; Jeannine Bachmann; Kerstin Fechtner; Helmut Friess; Ralf Kinscherf; Wulf Hildebrandt
Journal:  J Mol Med (Berl)       Date:  2007-03-02       Impact factor: 5.606

8.  Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases.

Authors:  R Breitkreutz; A Babylon; V Hack; K Schuster; M Tokus; H Böhles; E Hagmüller; L Edler; E Holm; W Dröge
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

9.  Creatine, L-carnitine, and ω3 polyunsaturated fatty acid supplementation from healthy to diseased skeletal muscle.

Authors:  Giuseppe D'Antona; Seyed Mohammad Nabavi; Piero Micheletti; Arianna Di Lorenzo; Roberto Aquilani; Enzo Nisoli; Mariangela Rondanelli; Maria Daglia
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

10.  Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection.

Authors:  Torben Kimhofer; Samantha Lodge; Luke Whiley; Nicola Gray; Ruey Leng Loo; Nathan G Lawler; Philipp Nitschke; Sze-How Bong; David L Morrison; Sofina Begum; Toby Richards; Bu B Yeap; Chris Smith; Kenneth G C Smith; Elaine Holmes; Jeremy K Nicholson
Journal:  J Proteome Res       Date:  2020-09-14       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.